open access

Vol 51, No 3 (2017)
Case reports
Submitted: 2016-10-26
Get Citation

Valproic acid malabsorption in 30 year-old female patient – Case study

Anna Jopowicz, Agnieszka Piechal, Iwona Kurkowska-Jastrzębska
DOI: 10.1016/j.pjnns.2017.02.006
·
Neurol Neurochir Pol 2017;51(3):259-262.

open access

Vol 51, No 3 (2017)
Case reports
Submitted: 2016-10-26

Abstract

Aim

Valproic acid (VPA) is used in epilepsy treatment and as a stabilizer in bipolar affective disorder for over 40 years. Although, the pharmacokinetic properties of valproic acid are well known, it is often forgotten that the formulation of the drug significantly influences its gastrointestinal absorption.

Case

We are describing the case of 30 year-old female patient, diagnosed at the age of 13 with juvenile myoclonic epilepsy. Complete ineffectiveness of the treatment was caused by malabsorption of sodium valproate and valproic acid in the patient. The change of the drug formulation resulted in a several times higher bioavailability of the drug and a partial improvement of the patient's clinical condition.

Commentary

Low concentration of valproic acid after administration the slow-released tablets are usually observed. However, a low bioavailability beside the bad compliance should be considered when the minimal level is extremely low during therapy. It is known that form of the drug, beside presence of food and its components, as well as gastrointestinal tract condition or interactions with other drugs can influence the drug level. Modification of the formulation of the drug may lead to improvement of absorption and increase its effectiveness.

Abstract

Aim

Valproic acid (VPA) is used in epilepsy treatment and as a stabilizer in bipolar affective disorder for over 40 years. Although, the pharmacokinetic properties of valproic acid are well known, it is often forgotten that the formulation of the drug significantly influences its gastrointestinal absorption.

Case

We are describing the case of 30 year-old female patient, diagnosed at the age of 13 with juvenile myoclonic epilepsy. Complete ineffectiveness of the treatment was caused by malabsorption of sodium valproate and valproic acid in the patient. The change of the drug formulation resulted in a several times higher bioavailability of the drug and a partial improvement of the patient's clinical condition.

Commentary

Low concentration of valproic acid after administration the slow-released tablets are usually observed. However, a low bioavailability beside the bad compliance should be considered when the minimal level is extremely low during therapy. It is known that form of the drug, beside presence of food and its components, as well as gastrointestinal tract condition or interactions with other drugs can influence the drug level. Modification of the formulation of the drug may lead to improvement of absorption and increase its effectiveness.

Get Citation

Keywords

Valproic acid, Absorption, Bioavailability

About this article
Title

Valproic acid malabsorption in 30 year-old female patient – Case study

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 51, No 3 (2017)

Pages

259-262

DOI

10.1016/j.pjnns.2017.02.006

Bibliographic record

Neurol Neurochir Pol 2017;51(3):259-262.

Keywords

Valproic acid
Absorption
Bioavailability

Authors

Anna Jopowicz
Agnieszka Piechal
Iwona Kurkowska-Jastrzębska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl